ProSomnus, Inc. today announced that the U.S. Patent and Trademark Office (USPTO) has allowed a patent application covering the Company’s proprietary automated manufacturing process for the Company’s precision medical devices; this is the third patent to issue in this family, including already-issued USPN 10,213,280 and USPN 9,808,327. ProSomnus’s intellectual property portfolio now includes 16 issued patents in the United States and other countries, encompassing more than 100 claims, in addition to trademarks, trade secrets and other patent applications in process.
ProSomnus’s FDA-cleared Precision OAT devices are a practical alternative to legacy oral devices and CPAP machines. In clinical studies, ProSomnus devices have demonstrated excellent efficacy and robust patient compliance relative to other treatment options. They reposition and stabilize the jaw during sleep, improving airflow through a patient’s pharyngeal space. ProSomnus Precision OAT devices consist of maxillary and mandibular aligners that are precision-manufactured with twin-mated posts, and are digitally milled to be patient-specific. Prescribed advancements can be achieved by removing the current upper- or lower-device arch and inserting the next arch in the mandibular advancement series.
“Our automated medical device manufacturing technologies, the subject of this patent and other patents in our portfolio, are an important component of what makes ProSomnus different. Every ProSomnus precision device is personalized and manufactured based on the anatomy and treatment plan for each patient,” said Len Liptak, Co-Founder and Chief Executive Officer for ProSomnus. “These patented technologies enable ProSomnus to service the rapidly growing demand for our precision sleep apnea devices without compromising the effectiveness, comfort, and consistency that healthcare providers and their patients require. The data generated from our digital manufacturing capabilities enable ProSomnus to continuously improve our processes, quality, and technologies.”